enoxacin
Trade name: penetrex
Approved
Dec 31, 1991
Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Enoxacin is bactericidal drugs, eradicating bacteria by interfering with DNA replication. Like other fluoroquinolones, enoxacin functions by inhibiting bacterial DNA gyrase and topoisomerase IV. The inhibition of these enzymes prevents bacterial DNA replication, transcription, repair and recombination. Enoxacin is active against many Gram-positive bacteria. After oral administration enoxacin is rapidly and well absorbed from the gastrointestinal tract. The antibiotic is widely distributed throughout the body and in the different biological tissues. Tissue concentrations often exceed serum concentrations. The binding of enoxacin to serum proteins is 35 to 40%. The serum elimination half-life, in subjects with normal renal function, is approximately 6 hours. Approximately 60% of an orally administered dose is excreted in the urine as unchanged drug within 24 hours. Enoxacin, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold. The compound should not be administered to patients with epilepsy or a personal history of previous convulsive attacks as may promote the onset of these disorders. — NCATS
Clinical trial activity
2 trials · 5 clinical orgs · 1 marketing orgs
Earliest trial started Apr 1, 2015 (NCT02483455)
Timeline
1990s
- Dec 31, 1991
Sanofi-Aventis — Earliest FDA Approval
- Dec 31, 1991
Sanofi-Aventis — NDA Secondary Org
- Dec 31, 1991
Sanofi-Aventis — NDA Organization
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Topoisomerase IVINHIBITOR
Topoisomerase IV inhibitor
- DNA gyraseINHIBITOR
DNA gyrase inhibitor
Approval history
- approvedDec 31, 1991
Chemistry & pharmacology
SMILES
CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2- Mol. weight
- 320.3189 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaEnoxacin ↗
- NCATS325OGW249P ↗
- ChEMBLCHEMBL826 ↗
Also known as
- 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid
- 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid
- 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
- 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
- alc-919
- at-2266
- at-2266
- ci-919
- ci-919
- comprecin
- comprecin
- enofloxacin
- enofloxacine
- enoksetin
- enoxacin
- enoxacin
- enoxacin
- enoxacin
- enoxacin
- enoxacin
- enoxacin
- enoxacin
- enoxacin
- enoxacin
- enoxacin
- enoxacina
- enoxacina
- enoxacine
- énoxacine
- énoxacine
- enoxacino
- enoxacino
- enoxacinum
- enoxacinum
- flumark
- flumark
- pd-107779
- pd-107779
- penetrex
- penetrex
- penetrex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04840823 | Phase 1/Phase 2 (Phase 2) | Mar 26, 2021 | Apotex, McGill University, Weizmann Institute of Science |
| NCT02483455 | Phase 2 | Apr 1, 2015 | ALC Therapeutics, LLC, Philadelphia Institute of Dermatology |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ALC Therapeutics, LLC | For profit | 1 | 1 | 1 | 2015 |
| Apotex | For profit | 1 | 0 | 1 | 2021 |
| McGill University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Philadelphia Institute of Dermatology | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Weizmann Institute of Science | Academic/Hospital | 1 | 0 | 1 | 2021 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Sanofi-Aventis | For profit | NDA2 | Dec 31, 1991 |
| Sanofi-Aventis | For profit | NDA | Dec 31, 1991 |